12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema

Hemodynamic Profiling: The Stevenson / Nohria Classification

Acute decompensated heart failure (ADHF) is a heterogeneous syndrome characterized by the rapid onset or worsening of symptoms and signs of heart failure requiring urgent medical evaluation and intervention. Rather than treating heart failure as a uniform entity, modern critical care management relies on rapid hemodynamic phenotyping developed by Stevenson and Nohria. This bedside classification stratifies patients along two primary physiological axes:

1. Congestion (Wet vs. Dry): Reflects elevated left ventricular filling pressures, clinically corresponding to a pulmonary capillary wedge pressure (PCWP) $> 18\text{ mmHg}$ or central venous pressure (CVP) $> 10-12\text{ mmHg}$. Clinical markers include orthopnea, paroxysmal nocturnal dyspnea, jugular venous distention (JVD), hepatojugular reflux, pulmonary crackles, ascites, and peripheral pitting edema.
2. Perfusion (Warm vs. Cold): Reflects adequacy of cardiac output and systemic tissue perfusion, clinically corresponding to a cardiac index (CI) $< 2.2\text{ L/min/m}^2$. Clinical markers include narrow pulse pressure (proportional pulse pressure $[\text{SBP} - \text{DBP}] / \text{SBP} < 25\%$), cool clammy extremities, delayed capillary refill, mental status changes (lethargy, obtundation), prerenal azotemia with worsening renal function, and metabolic lactic acidosis.

This 2x2 matrix divides patients into four distinct hemodynamic profiles:

• Profile A ("Warm and Dry"): Compensated heart failure with normal filling pressures (PCWP $\le 18\text{ mmHg}$) and preserved tissue perfusion (CI $\ge 2.2\text{ L/min/m}^2$). These patients do not require acute in-hospital resuscitation; therapy focuses on optimizing oral guideline-directed medical therapy (GDMT).
• Profile B ("Warm and Wet"): The most common presentation (~65% to 70% of ADHF hospitalizations). Characterized by elevated filling pressures (PCWP $> 18\text{ mmHg}$) but preserved systemic perfusion (CI $\ge 2.2\text{ L/min/m}^2$). The primary therapeutic objective is rapid decongestion using intravenous loop diuretics combined with intravenous vasodilators (nitroglycerin or sodium nitroprusside) to reduce preload and afterload.
• Profile C ("Cold and Wet"): Represents decompensated heart failure with cardiogenic hypoperfusion or true cardiogenic shock (~15% to 20% of cases). Characterized by severe congestion (PCWP $> 18\text{ mmHg}$) and severely depressed cardiac output (CI $< 2.2\text{ L/min/m}^2$). Systemic vascular resistance (SVR) is markedly elevated as a compensatory response:

$\text{SVR} = 80 \times \frac{\text{MAP} - \text{CVP}}{\text{CO}}$

Therapy requires restoring perfusion before aggressive diuresis. Inotropic agents (dobutamine or milrinone) are indicated to augment contractility, vasopressors (norepinephrine) are added if mean arterial pressure (MAP) is $< 65\text{ mmHg}$, and mechanical circulatory support (MCS; e.g., intra-aortic balloon pump, Impella, or venoarterial ECMO) is initiated for refractory shock.

• Profile L ("Cold and Dry"): Characterized by low perfusion (CI $< 2.2\text{ L/min/m}^2$) without congestion (PCWP $\le 18\text{ mmHg}$). This profile represents hypovolemia or excessive diuretic therapy in a patient with chronic cardiac dysfunction. Management requires cautious, incremental volume administration (crystalloid boluses of $250\text{ to }500\text{ mL}$) under close hemodynamic monitoring to raise preload along the ascending limb of the Frank-Starling curve.

---

Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema

Acute cardiogenic pulmonary edema (ACPE) represents a medical emergency in which rapid hydrostatic transudation of fluid into the pulmonary interstitium and alveoli leads to severe ventilation-perfusion mismatch, shunt physiology, hypoxemic respiratory failure, and markedly increased work of breathing. Noninvasive ventilation (NIV)—encompassing continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP)—is a first-line intervention that alters cardiopulmonary hemodynamics through positive intrathoracic pressure.

Cardiopulmonary Hemodynamics of Positive Intrathoracic Pressure

Positive intrathoracic pressure exerts favorable hemodynamic effects in acute left-sided heart failure:

1. Reduction of LV Afterload: Left ventricular afterload is determined by LV transmural systolic pressure, which is the pressure difference between the interior of the left ventricle and the surrounding pleural space:

$\text{Transmural LV Systolic Pressure} = P_{\text{LV}} - P_{\text{pleural}}$

In spontaneous respiratory distress, vigorous inspiratory efforts generate highly negative pleural pressures (down to $-15\text{ to }-25\text{ cmH}_2\text{O}$), which dramatically increases transmural LV systolic wall tension and afterload. By delivering continuous positive airway pressure, NIV elevates $P_{\text{pleural}}$, lowering transmural pressure and immediately decreasing LV afterload. This facilitates systolic emptying and enhances forward stroke volume. 2. Reduction of LV Preload: Positive intrathoracic pressure decreases the pressure gradient for systemic venous return to the right heart, reducing right and left ventricular end-diastolic volumes. In the failing, volume-overloaded ventricle operating on the plateau or descending limb of the Frank-Starling curve, this reduction in preload lowers pulmonary capillary hydrostatic pressure without compromising cardiac output. 3. Alveolar Recruitment and Gas Exchange: Continuous positive end-expiratory pressure recruits fluid-filled and atelectatic alveoli, increases functional residual capacity (FRC), shifts fluid from alveolar spaces back into the pulmonary interstitium, and improves dynamic pulmonary compliance. 4. Work of Breathing and Metabolic Unloading: In ACPE, the work of breathing can consume up to $20\%\text{ to }30\%$ of total cardiac output. NIV offloads the respiratory musculature, reducing whole-body oxygen consumption and redistributing limited forward cardiac output toward vital systemic organs.

The 3CPO Trial and Clinical Application

The landmark 3CPO Trial (Gray et al., NEJM 2008) evaluated 1,069 patients with acute cardiogenic pulmonary edema randomized to standard oxygen therapy, CPAP ($10\text{ cmH}_2\text{O}$), or noninvasive bilevel positive pressure ventilation (inspiratory positive airway pressure [IPAP] $8\text{ to }20\text{ cmH}_2\text{O}$, expiratory positive airway pressure [EPAP] $4\text{ to }10\text{ cmH}_2\text{O}$). Key conclusions include:

• Rapid Physiological Improvement: Both CPAP and BiPAP resulted in faster resolution of dyspnea, rapid normalization of pH and $\text{PaCO}_2$, and faster improvement in hypercapnia within the first hour compared to standard oxygen therapy ($p < 0.001$).
• Intubation and Mortality: The 7-day mortality (~9.5%) and 30-day mortality were not significantly different between noninvasive ventilation and standard oxygen therapy, and intubation was rare and similar in both arms (2.8% vs. 2.9%). Meta-analyses that pool smaller trials (for example, the 2019 Cochrane review) do show fewer intubations and lower hospital mortality with NIV, which is why NIV remains first-line for respiratory distress from cardiogenic pulmonary edema.
• CPAP vs. BiPAP Equivalence: There was no significant difference in clinical efficacy, intubation rates, or mortality between CPAP and BiPAP. Furthermore, 3CPO refuted earlier observational concerns that BiPAP was associated with higher rates of acute myocardial infarction.

---

Loop Diuretic Therapy and the DOSE Trial

Intravenous loop diuretics (furosemide, bumetanide, torsemide) represent the cornerstone of therapy for volume-overloaded ADHF. These agents act on the luminal $\text{Na}^+-\text{K}^+-2\text{Cl}^-$ symporter in the thick ascending limb of Henle's loop, blocking the reabsorption of sodium and chloride and producing potent natriuresis and chloruresis.

Acute Hemodynamic Effects: The Biphasic Action

Loop diuretics exert a distinct biphasic physiological response:

1. Early Prostaglandin-Mediated Venodilation (5 to 15 minutes): Prior to the onset of urine output, intravenous furosemide stimulates renal and systemic prostaglandin release, causing systemic venodilation. This rapidly expands capacitance veins, reduces systemic venous return, and lowers pulmonary capillary wedge pressure within minutes of bolus injection.
2. Late Natriuretic Phase (30 to 60 minutes): Natriuresis and diuresis peak at 1 to 2 hours, reducing total intravascular and interstitial fluid volume.

The DOSE Trial (Diuretic Optimization Strategies Evaluation)

Historically, clinicians debated whether continuous diuretic infusion was superior to intermittent boluses and whether high-dose regimens risked acute renal injury. The DOSE Trial (Felker et al., NEJM 2011) enrolled 308 patients with acute decompensated heart failure in a 2x2 factorial randomized design comparing:

• High-Dose vs. Low-Dose: High dose was defined as $2.5\text{ times}$ the previous total daily oral loop diuretic dose administered intravenously (e.g., if taking furosemide $80\text{ mg}$ PO daily, the patient received $200\text{ mg}$ IV daily). Low dose was defined as $1.0\text{ times}$ the oral home dose intravenously.
• Continuous Infusion vs. Intermittent Bolus: Continuous IV infusion vs. IV boluses administered every 12 hours.

Key findings of the DOSE trial established the modern standard of care:

• Continuous vs. Bolus: There was no statistically significant difference between continuous infusion and intermittent bolus dosing in terms of patient-reported global symptom relief or change in serum creatinine at 72 hours.
• High-Dose vs. Low-Dose: The high-dose strategy demonstrated favorable secondary endpoints: greater net fluid loss, greater weight loss, and more rapid dyspnea relief compared to the low-dose strategy.
• Renal Safety: Although the high-dose group experienced a higher incidence of transient worsening renal function ($> 0.3\text{ mg/dL}$ rise in serum creatinine at 72 hours; $23\%$ vs. $14\%$), this bump was transient, and renal function at 60 days was identical between groups. Long-term adverse events, rehospitalizations, and mortality were not increased in the high-dose cohort.

Urine Sodium and Natriuretic Response Monitoring

Current clinical guidelines emphasize assessing diuretic response early. A spot urine sodium concentration should be measured at 2 hours following diuretic administration:

• Adequate Natriuresis: Urine sodium $> 50-70\text{ mEq/L}$ or urine output $> 100-150\text{ mL/hr}$ over the first 6 hours. Continue current diuretic regimen.
• Diuretic Resistance: Urine sodium $< 50\text{ mEq/L}$ or urine output $< 100\text{ mL/hr}$. Immediately double the intravenous loop diuretic dose (up to ceiling doses: furosemide $160-200\text{ mg}$ IV bolus). If resistance persists, initiate sequential nephron blockade by adding a thiazide-like diuretic (e.g., oral metolazone $2.5-5\text{ mg}$ daily or IV chlorothiazide $500\text{ mg}$ BID) or intravenous acetazolamide ($500\text{ mg}$ daily, as supported by the ADVOR trial) to inhibit proximal tubular sodium reabsorption.

---

Vasodilator Therapy and the SCAPE Emergency Protocol

Intravenous vasodilators play an indispensable role in patients with acute hypertensive heart failure and normal or elevated systemic vascular resistance.

Pathophysiology of SCAPE (Sympathetic Crashing Acute Pulmonary Edema)

Sympathetic Crashing Acute Pulmonary Edema (SCAPE) represents the most extreme, hyperacute presentation of acute heart failure. Unlike chronic gradual volume accumulation over weeks, SCAPE is characterized by:

• Abrupt sympathetic surge triggering massive systemic vasoconstriction.
• Marked elevation of systolic blood pressure (frequently $> 180-200\text{ mmHg}$) and severe afterload mismatch.
• Acute central redistribution of blood from the splanchnic and venous capacitance reservoirs into the pulmonary circulation.
• Alveolar flooding developing over minutes to hours ("flash pulmonary edema").
• Intravascular Euvolemia: Patients in SCAPE are often not total-body hypervolemic; their primary pathology is fluid maldistribution due to afterload overload.

High-Dose Nitroglycerin SCAPE Protocol

Nitroglycerin acts predominantly as a venodilator at lower doses ($< 100\text{ mcg/min}$), expanding systemic venous capacitance and lowering LV preload. At high doses ($> 100-200\text{ mcg/min}$), it acts as a potent arterial vasodilator, reducing systemic vascular resistance, decreasing LV afterload, and breaking the vicious cycle of afterload mismatch:

1. Simultaneous Noninvasive Ventilation: Apply CPAP at $8-10\text{ cmH}_2\text{O}$ or BiPAP immediately to support alveolar recruitment and lower LV transmural wall stress.
2. High-Dose Nitroglycerin Bolus: Administer an initial intravenous bolus of $400\text{ to }1,000\text{ mcg}$ over 1 to 2 minutes (or administer repeated sublingual nitroglycerin $400\text{ mcg}$ tablets/sprays every 2 minutes while IV access is established).
3. Aggressive Continuous Infusion: Start the IV infusion at $100\text{ to }200\text{ mcg/min}$, rapidly titrating upward by $50\text{ to }100\text{ mcg/min}$ every 3 to 5 minutes based on blood pressure response (maximum doses up to $400\text{ mcg/min}$) until SBP is reduced by $20\%\text{ to }30\%$ or reaches $< 140-150\text{ mmHg}$.
4. Deferred Diuretic Administration: Administer low-to-moderate dose intravenous furosemide ($20-40\text{ mg}$) only after blood pressure and pulmonary edema have improved under vasodilator control.

Sodium Nitroprusside: Balanced Dilation and Toxicity

Sodium nitroprusside is a direct, balanced arterial and venous vasodilator with an immediate onset and short duration of action ($1-2\text{ minutes}$). By releasing nitric oxide non-enzymatically in vascular smooth muscle, it dramatically reduces both preload (PCWP) and afterload (SVR), making it an exceptional agent for severe hypertensive heart failure, acute aortic regurgitation, and acute mitral regurgitation.

However, sodium nitroprusside carries substantial metabolic risks:

• Cyanide and Thiocyanate Toxicity: Each molecule of sodium nitroprusside contains five cyanide groups. In the bloodstream, nitroprusside reacts with hemoglobin to release free cyanide ions. Hepatic rhodanese converts cyanide to thiocyanate using sulfur donors (thiosulfate), and thiocyanate is excreted renally with a half-life of 3 to 7 days.
• Risk Factors: Infusion rates $> 2-3\text{ mcg/kg/min}$, duration $> 48\text{ hours}$, pre-existing hepatic impairment (impairs conversion of cyanide to thiocyanate), or renal failure (impairs thiocyanate excretion).
• Clinical Manifestations:
  • Cyanide Poisoning: Inhibits cytochrome c oxidase in the mitochondrial electron transport chain, blocking oxidative phosphorylation. Presents as profound, refractory lactic acidosis, mental status deterioration, and an abnormally elevated mixed venous oxygen saturation ($S_v\text{O}_2 > 85-90\%$) due to inability of tissues to extract oxygen.
  • Thiocyanate Poisoning: Manifests as central nervous system toxicity, including delirium, confusion, tremor, hyperreflexia, tinnitus, hallucination, and seizures.
• Treatment: Discontinue nitroprusside immediately. For cyanide toxicity, administer hydroxocobalamin ($5\text{ g}$ IV over 15 minutes), which binds cyanide to form non-toxic cyanocobalamin (vitamin $\text{B}_{12}$) excreted in urine. Alternatively, administer sodium thiosulfate ($12.5\text{ g}$ IV) to provide sulfur substrates for hepatic clearance.

---

Ultrafiltration in Decompensated Heart Failure: The CARRESS-HF Trial

Extracorporeal ultrafiltration (UF) mechanically removes plasma water across a semipermeable membrane via convective hydrostatic pressure, allowing precise control of fluid removal rates without neurohormonal activation or electrolyte derangements associated with loop diuretics.

The CARRESS-HF Trial (Cardiorenal Rescue Study in ADHF)

The CARRESS-HF Trial (Bart et al., NEJM 2012) tested whether ultrafiltration was superior to stepped pharmacologic therapy in patients with ADHF complicated by persistent congestion and worsening renal function (cardiorenal syndrome). Patients were randomized to:

1. Stepped Pharmacologic Therapy: Algorithm-driven diuretic titration, sequential nephron blockade with metolazone, and intravenous vasodilators or inotropes targeted to maintain urine output $> 3-5\text{ L/day}$.
2. Ultrafiltration: Fixed ultrafiltration rate of $200\text{ mL/hr}$ adjusted only for hemodynamic instability.

Trial Outcomes and Clinical Implications

• Renal Function: At 96 hours, patients in the ultrafiltration group experienced a significantly greater increase in serum creatinine ($+0.23\text{ mg/dL}$ vs. $-0.04\text{ mg/dL}$ in the pharmacologic arm, $p = 0.003$).
• Fluid and Weight Loss: Weight loss at 96 hours was virtually identical between the two arms (~$5.7\text{ kg}$ vs. ~$5.5\text{ kg}$, $p = 0.58$).
• Adverse Events: The ultrafiltration group experienced significantly higher rates of serious adverse events ($72\%$ vs. $57\%$, $p = 0.03$), including catheter-related bacteremia, circuit thrombosis, hemorrhage, and access-site vascular complications.
• Conclusion: Routine ultrafiltration is inferior to stepped pharmacologic therapy for patients with acute decompensated heart failure and worsening renal function. Ultrafiltration is strictly reserved as salvage therapy for refractory volume overload unresponsive to maximized sequential diuretic regimens and inotropic therapy.